Mon Dec 23 23:28:00 UTC 2024: **Senores Pharmaceuticals IPO Oversubscribed 13.9 Times**

**Mumbai, India –** Senores Pharmaceuticals Ltd.’s initial public offering (IPO) has been massively oversubscribed, reaching 13.9 times its total offering size by the end of the second day of subscription. The ₹582.1 crore (approximately $70 million USD) offering, comprising a fresh issue of ₹500 crore and an offer for sale of ₹82.1 crore, has seen particularly strong demand from retail investors.

The IPO, priced between ₹372 and ₹391 per share, has a projected listing price of ₹611 based on the grey market premium (GMP) of ₹220, representing a potential premium of 56.27%. It is crucial to note that the GMP is unofficial and based on speculation.

Proceeds from the IPO will be used to fund various initiatives, including:

* Capital expenditure for a new sterile injection manufacturing facility at its Atlanta subsidiary, Havix Group Inc. (Aavis Pharmaceuticals).
* Repayment of borrowings.
* Working capital requirements for Senores Pharmaceuticals and its subsidiaries, including Havix and Ratnatris Pharmaceutical Pvt.
* Inorganic growth through acquisitions and other strategic initiatives.

Senores Pharmaceuticals is a global research-driven pharmaceutical company specializing in generic pharmaceutical products for regulated markets (primarily the US, Canada, and the UK) and emerging markets. The company has received approvals for 19 abbreviated new drug applications and operates across 43 countries. It also manufactures active pharmaceutical ingredients (APIs) and critical care injectables.

While the high level of oversubscription is encouraging, potential investors are reminded that IPOs are subject to market risks and should conduct thorough due diligence before investing. Consulting a financial advisor and reviewing the red herring prospectus is strongly recommended. The breakdown of subscription includes 0.35 times from Qualified Institutional Buyers, 24.63 times from Non-Institutional Investors and 10.14 times from Employees.

Read More